Sign up
Pharma Capital

Lojuxta 'exceeding expectations' - Amryt Pharma's Joe Wiley

Joe Wiley, chief executive of Amryt Pharma PLC (LON:AMYT) tells Proactive a product that it licensed the rights to is performing better than expected.

Lojuxta treats a rare and life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.

Revenues from the treatment were €5.75mln for the six months ended June; the company’s total sales for the period were €6.18mln.

 

View full AMYT profile

Amryt Pharmaceuticals Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.